243 related articles for article (PubMed ID: 31807995)
1. Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis.
Fan X; Men R; Ni P; Lu C; Si T; Ma Y; Yang L
Clin Rheumatol; 2020 Mar; 39(3):795-803. PubMed ID: 31807995
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis.
Cheng C; Wang Z; Wang L; Zhao J; Wang Q; Tian X; Li M; Zeng X
Clin Rheumatol; 2021 May; 40(5):1819-1826. PubMed ID: 33067770
[TBL] [Abstract][Full Text] [Related]
3. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
5. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
[TBL] [Abstract][Full Text] [Related]
6. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
7. [Response to Primary Biliary Cholangitis Treatment: Influencing Factors and the Role in Prognosis Prediction].
Liu Y; Fan X; Shen Y; Men R; Guo Y; Yang L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 54(5):930-936. PubMed ID: 37866948
[TBL] [Abstract][Full Text] [Related]
8. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
[TBL] [Abstract][Full Text] [Related]
9. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
10. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
Corpechot C; Chazouillères O; Poupon R
J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study.
Liu Y; Han K; Liu C; Duan F; Cheng J; Yang S
Can J Gastroenterol Hepatol; 2021; 2021():5557814. PubMed ID: 33791253
[TBL] [Abstract][Full Text] [Related]
12. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
[TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics of Concomitant Systemic Lupus Erythematosus and Primary Biliary Cirrhosis: A Literature Review.
Shizuma T
J Immunol Res; 2015; 2015():713728. PubMed ID: 26090497
[TBL] [Abstract][Full Text] [Related]
15. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.
Cortez-Pinto H; Liberal R; Lopes S; Machado MV; Carvalho J; Dias T; Santos A; Agostinho C; Figueiredo P; Loureiro R; Martins A; Alexandrino G; Cotrim I; Leal C; Presa J; Mesquita M; Nunes J; Gouveia C; Vale AHE; Alves AL; Coelho M; Maia L; Pedroto I; Banhudo A; Pinto JS; Gomes MV; Oliveira J; Andreozzi V; Calinas F
United European Gastroenterol J; 2021 Jul; 9(6):699-706. PubMed ID: 34102008
[TBL] [Abstract][Full Text] [Related]
16. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.
Terziroli Beretta-Piccoli B; Stirnimann G; Mertens J; Semela D; Zen Y; Mazzucchelli L; Voreck A; Kolbus N; Merlo E; Di Bartolomeo C; Messina P; Cerny A; Costantini S; Vergani D; Mieli-Vergani G;
J Autoimmun; 2021 Jan; 116():102578. PubMed ID: 33229138
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
Poupon RE; Eschwège E; Poupon R
J Hepatol; 1990 Jul; 11(1):16-21. PubMed ID: 1975819
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis.
Gatselis NK; Goet JC; Zachou K; Lammers WJ; Janssen HLA; Hirschfield G; Corpechot C; Lindor KD; Invernizzi P; Mayo MJ; Battezzati PM; Floreani A; Pares A; Lygoura V; Nevens F; Mason AL; Kowdley KV; Ponsioen CY; Bruns T; Thorburn D; Verhelst X; Harms MH; van Buuren HR; Hansen BE; Dalekos GN;
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):684-692.e6. PubMed ID: 31419573
[TBL] [Abstract][Full Text] [Related]
19. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.
Harms MH; Lammers WJ; Thorburn D; Corpechot C; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Dalekos GN; Bruns T; Parés A; Mason AL; Verhelst X; Kowdley KV; Goet JC; Hirschfield GM; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2018 Feb; 113(2):254-264. PubMed ID: 29231188
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases.
Efe C; Purnak T; Ozaslan E; Ozbalkan Z; Karaaslan Y; Altiparmak E; Muratori P; Wahlin S
Scand J Gastroenterol; 2011 Jun; 46(6):732-7. PubMed ID: 21348808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
